Vermillion, Inc. (NASDAQ:VRML) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Condition.
On August 9, 2017, Vermillion, Inc. (the “Company”) issued a press release reporting financial results for the three and six months ended June 30, 2017.A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section.Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in such filing.
Item 9.01Financial Statements and Exhibits.
The following exhibit is being furnished as part of this report.
(d)Exhibit No.Description
99.1Press Release issued by Vermillion, Inc. on August 9, 2017
VERMILLION, INC. ExhibitEX-99.1 2 c617-20170809xex99_1.htm EX-99.1 2017-08-09 8K Ex 991 Exhibit 99.1 Vermillion Reports Second Quarter 2017 Results Conference Call at 4:30 p.m. ET Today AUSTIN,…To view the full exhibit click here
About Vermillion, Inc. (NASDAQ:VRML)
Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.
